Drospirenone detected in postmortem blood of a young woman with pulmonary thromboembolism: A case report and review of the literature

摘要

Progestin/estrogen oral contraceptives have some side effects, including venous thromboembolism. To alleviate side effects, improvements have been made to low-dose oral contraceptives, including reductions in the amount of estrogen and/or changes the type of progestin. A compound drug containing 3 mg drospirenone and 20 mu g ethinylestradiol (DRSP/EE20, YAZ (R)) was released in overseas markets in 2006, and in Japan in 2010 as a newly developed low-dose medicines. This drug is expected to have lower side effects.